€38 million for personalised medicine solutions to cardiovascular, metabolic or kidney diseases

The European Partnership for Personalised Medicine (EP PerMed) is a 10-year European Partnership launched under Horizon Europe with a vision to improve health outcomes within sustainable healthcare systems through research, development, innovation and implementation of personalised medicine approaches for the benefit of patients, citizens, and society.

EP PerMed is now inviting proposals for its Joint Transnational Call (JTC) 2026 – Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026) – which will fund research projects in human health on innovative PM strategies for patients with cardiovascular, metabolic or kidney diseases.

Around €38 million is available to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thereby enhancing the competitiveness in Europe and beyond in this field.

Research projects may focus on a single disease or explore the three conditions in combination. Proposals should address one or more of the following aspects:

• Innovative personalised therapeutic approaches.
• Monitoring of treatment response in patients in order to tailor treatment pathways.
• Early disease risk prediction and prevention of disease worsening or comorbidities.

Projects are required to include a dedicated work package focussing on the question of the translation or implementation of the research outcomes into clinical practice with a focus on eg patient outcome, patient preferences, costs, reimbursement, education (to healthcare providers, patients and citizens), ELSA (ethical, legal and societal aspect) or accessibility at the point of care.

Only transnational projects will be funded. Consortia are strongly encouraged to include a mix of partners from academia, the clinical/public health sector, and private for-profit (industry) partners in line with the crosscutting/multidisciplinary nature of the call. The active representation of patients or citizens as part of research projects is encouraged.

The maximum number of partners is six. The maximum number of partners can be seven if the consortium includes a third partner of the same country, in which case funding must be requested from at least two different funders of the respective country; this applies to only one country per consortium, including partners on own funds. No more than two partners from the same country, including partners on own funding, is allowed.

The following countries (27) are participating in the call: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, South Africa, Spain, Sweden and Türkiye.

Individual groups are funded by their respective EP PerMed funding organisations. Applications are therefore subject to eligibility criteria and regulations of the individual funding organisations, and applicants are strongly advised to contact their national representatives to confirm their eligibility.